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a  b  s  t  r  a  c  t
Early  diagnosis  and  access  to treatment  for infants  with  human  immunodeﬁciency  virus-1  (HIV-1)  is
critical  to reduce  infant  mortality.  The  lack  of  simple  point-of-care  tests  impedes  the  timely  initiation  of
antiretroviral  therapy.  The  development  of FINA,  ﬁltration  isolation  of nucleic  acids,  a  novel DNA  extrac-
tion  method  that  can  be performed  by clinic  personnel  in  less  than  2 min  has  been  reported  previously.





that  allow  sensitive  quantitation  of as little  as  10 copies  of HIV-1  proviral  DNA  and detection  of  3  copies
extracted  from  100  l of whole  blood.  An  internal  control  to detect  PCR  inhibition  was  also incorporated.
In  a preliminary  ﬁeld  evaluation  of  61  South  African  infants,  the  FINA test  demonstrated  100%  sensitivity
and  speciﬁcity.  The  proviral  copy  number  of  the  infant  specimens  was  quantiﬁed,  and  it was  established
that  100  microliters  of  whole  blood  is  required  for  sensitive  diagnosis  of infants.
©  2015  The  Authors.  Published  by  Elsevier  B.V.  This  is  an  open  access  article  under the  CC  BY-NC-ND. Introduction
Infant HIV infection remains a signiﬁcant problem. An estimated
90,000 new pediatric infections were reported in 2010, mostly
n limited resource settings (WHO  Progress Report, 2011). Early
nfant diagnosis of these cases would allow for prompt initiation of
ighly active antiretroviral therapy alleviating suffering and pre-
enting premature death in these infants. WHO  recommends that
ll infants born to HIV-1 positive mothers should be tested at 4–6
eeks of age, using a virological test (WHO, 2010); however, testingates are too low. In 2011, only 35% of infants born to HIV-1 posi-
ive mothers were tested globally, with only 4 sub-Saharan African
Abbreviations: DBS, dried blood spot; FINA, ﬁltration isolation of nucleic acids;
OC, point-of-care; LOD, limit of detection; LOQ, limit of quantitation; HPR, hydrox-
pyruvate reductase; IC, internal control.
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countries responsible for more than 50% of HIV-1 exposed infants
(WHO  Global Update on HIV Treatment, 2013).
Access to virological infant testing is challenging in low resource
settings. Persistence of maternal antibodies in an infant’s blood lim-
its the diagnostic utility of rapid HIV antibody tests in determining
the status of HIV-exposed infants. PCR-based tests for the detection
of proviral HIV-1 DNA are the current standard for infant diagno-
sis, as these tests are both sensitive and speciﬁc. However, many
barriers exist in the implementation of PCR testing protocols in
resource-limited areas. Current methods for nucleic acid puriﬁca-
tion are time consuming, require skilled processing, and use costly
reagents and equipment (Roberts et al., 2012). There is an urgent
need to improve access to early infant diagnosis particularly at
peripheral sites where, increasingly, HIV clinical management is
being provided. This is consistent with the need to decentralize
treatment to improve access and retention in care (Kredo et al.,
2013).
To improve access to PCR-based diagnosis in remote sites, a test-
ing protocol of collection of dried blood spots (DBS) at the site of
treatment, transportation to central laboratories for testing and the
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ommunication of results back to the DBS collection site has been
ecommended by WHO  (WHO  Global Update on HIV Treatment,
013). However, logistical problems associated with sample acqui-
ition and transportation cause delays in returning results to the
BS collection site. In a recent review of early infant diagnosis pro-
rams, it was reported that many infants are lost from care due to
ime to results which can be as much as 5 months and that only
alf the test results are communicated to the infant’s caregivers
Ciaranello et al., 2011). An early infant diagnostic that provides
he results during the initial clinic visit may  signiﬁcantly increase
he number of infants enrolled in antiretroviral therapy and should
igniﬁcantly decrease infant mortality.
The use of ﬁltration isolation of nucleic acids (FINA) as a viable
ethod for point-of-care extraction of leukocyte DNA from whole
lood for detection of the HIV-1 provirus by PCR with high degrees
f sensitivity and speciﬁcity has been demonstrated previously
Jangam et al., 2009). Processing by this method entraps DNA from
ysed whole blood in a glass-ﬁber disk that can be washed to
emove inhibitory components. The FINA process extracts cellu-
ar DNA from whole blood in less than 2 min. The disk containing
he cellular DNA can then be put directly into a tube for PCR, either
mmediately or stored desiccated for more than a month. A qPCR
rototype developed for use at the point-of-care (POC) that util-
zes FINA extraction was reported recently (Jangam et al., 2013.)
his system uses a glass ﬁber membrane to extract the DNA that is
nserted directly into a disposable PCR assay card that includes on-
oard reagent storage. The battery-operated analyzer rehydrates
he lyophilized PCR mastermix, performs real-time PCR and reports
he results to the user (Jangam et al., 2013.)
This report veriﬁes the FINA method for the sensitive detec-
ion of proviral HIV DNA using a model system to establish the
imit of detection (LOD) and quantitation (LOQ) of an improved ver-
ion of the assay, and describes the introduction of an exogenous
nternal control to report PCR inhibition. Additionally, the clinical
erformance of the assay was evaluated with fresh blood samples
btained from HIV-exposed infants at Cape Town, South Africa. The
roviral copy number in each of these clinical samples was  calcu-
ated by comparison of the Cq of each sample to a standard curve
un simultaneously. This copy number information is critical for
etermining the blood volume required to achieve the assay sensi-
ivity necessary to diagnose HIV infection in infants using the POC
CR infant diagnostic in development (Jangam et al., 2013).
. Materials and methods
.1. Reference strains
8E5-LAV cells (Folks et al., 1991) harboring a single copy of
he HIV-1 provirus were obtained from the Virology Quality
ssurance Laboratory (VQA; Rush Presbyterian/St. Luke’s Medical
enter, Chicago, IL) as frozen cell pellets of 4000 cells/l. Cell
ount was veriﬁed as described previously (Jangam et al., 2009).
ells were diluted in freezing medium (90% fetal bovine serum,
0% dimethyl sulfoxide) to concentrations ranging from 0.5 to
00 cells/l to be spiked into 100 l of fresh HIV-1-negative
DTA-treated whole blood samples (Core Lab, NorthShore Uni-
ersity HealthSystems, Evanston, IL) to create a standard curve
f copy numbers 5–4000. These spiked samples were used dur-
ng assay development and testing and to establish standard
urves during testing of clinical samples. Standards of 8E5-LAV
ells containing 20, 10, 5 and zero copies of the HIV-1 provirus,
btained from VQA, were used to assess the limit of detection
nd quantitation. The copy controls were prepared as described
n the VQA HIV DNA Control Standard Operating Procedure
https://www.hanc.info/labs/labresources/vqaResources/Pages/Ascal Methods 214 (2015) 37–42
saySpeciﬁcSops.aspx; VQA SOP for DNA PCR assays v5 03-13-
2012). To test for single copy sensitivity of the assay, 8e5-LAV cells
were diluted to 0.1 cell/l and spiked into blood samples at one
proviral copy per sample and processed as described below.
2.2. Clinical samples
DNA was  extracted using FINA modules from 61 EDTA-treated
whole blood samples tested at the National Health Laboratory
Service Virology Laboratory, Groote Schuur Hospital, Cape Town,
South Africa. Blood samples were collected by heel stick into
Microtainers with a scoop (Becton Dickinson; San Diego, CA) or
MiniCollect tubes with a funnel (Greiner Bio-One; Monroe, NC)
from infants less than 1 year of age. Total Nucleic Acid PCR (Roche
AmpliPrep/COBAS Taqman HIV-1) was performed on 100 l whole
blood precisely as described in the product insert. Samples identi-
ﬁed as HIV positive in the Total Nucleic Acid assay which contained
≥100 l residual specimen were paired with an equal number
of negative samples for blinded FINA analysis. The samples were
processed up to the qPCR assay, and the ﬁlter disks containing the
DNA were dried and shipped back to U.S. for qPCR testing. Before
the study in Cape Town was initiated, a standard curve of 10, 40,
400 and 4000 8e5-LAV cells spiked into whole blood in triplicate
were processed up to the qPCR analysis and the dried ﬁlters were
stored until the Cape Town samples were ready to be tested by
qPCR. After the all the samples were tested, the code was provided
to Northwestern University and the assay sensitivity and speciﬁcity
was determined.
2.3. DNA isolation
Cellular DNA was extracted from fresh whole blood by the FINA
method, as described previously (Jangam et al., 2009) with some
changes to the sizes of the FINA components. Brieﬂy, a Fusion 5
membrane disk (diameter, 8.35; Whatman, Inc., Florham Park, NJ)
was sandwiched between a square 707 blotter pad (25 by 25 mm;
VWR  International, West Chester, PA) and a thin sheet of Paraﬁlm
(Bemis Flexible Packaging; Neenah, WI)  with a 7.14-mm-diameter
hole in the center such that the hole of the Paraﬁlm left the cen-
ter of the Fusion 5 disk exposed (Fig. 1). Contact between the
disk and the blotter pad was  ensured by pressing the Paraﬁlm
ﬁrmly to stick it to the blotter pad around all edges of the disk.
Blood that had been lysed by adding Triton-X (Sigma Chemicals;
St. Louis MO)  to a ﬁnal concentration of 1% in the blood sample
was added to the disk and allowed to soak in completely, fol-
lowed by a single wash of 600–1000 l of 10 mM NaOH, until the
disk appeared white, indicating clearance of the hemoglobin. The
Paraﬁlm was then peeled off and the disk was separated from the
blotter pad with clean forceps, and placed into and stuck to the
side of a 200 l PCR tube that had been prepared with a circular
sticker made from PCR-safe, double-sided adhesive (3 M Double-
Coated Polyester Diagnostic tape, product number 9965; diameter,
5.1 mm;  3 M Medical Specialties, St. Paul, MN). This ﬁlter was used
as the template for subsequent qPCR ampliﬁcation and detection.
After the ﬁlter was placed in the PCR tube, the clinical samples from
Cape Town were dried overnight in a box containing calcium sulfate
desiccant, capped, and placed in a foil pouch with silica desiccant
and sent to Northwestern University for qPCR testing. The stability
of the dried ﬁlter had been previously established (Jangam et al.,
2009).
2.4. qPCR ampliﬁcation and detectionPCR ampliﬁcation and detection were performed using the
Abbott HIV-1 RealTime Assay (Abbott Molecular Inc., Des  Plaines,
IL) reagent kit including the primers & probes and their PCR
S.M. McFall et al. / Journal of Virological Methods 214 (2015) 37–42 39
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if the assay can detect a single copy, 8e5-LAV cells were diluted
such that 84 replicates contained a single copy. The Stratagene
MxPro software determined that 24 of 84 (29%) single copy sam-
ples were positive. Upon inspection of the remaining curves, it
Table 1
Detection and Quantitation of VQA copy standards with FINA extraction and Abbott
HIV-1 RealTime Assay primers and probes. NA = not applicable.
Detection Quantitationig. 1. Schematic of FINA in-house module production. An 8.35 mM diameter Fusio
f  Paraﬁlm containing a 7.14-mm-diameter hole in the center such that the hole o
y  pipet.
hermal cycling protocol. A number of modiﬁcations to Abbott’s
eagents & protocol were made to adapt the assay for eventual
ncorporation into the FINA POC instrument under development
Jangam et al., 2013). ZO5 polymerase (Roche Molecular Systems,
nc., Branchburg, NJ) was substituted for Tth polymerase used in
he Abbott assay because ZO5 is available in a form that is more
menable to lyophilization which will be necessary for inclusion
n a POC assay card. The reverse transcription step was  omitted
s described previously (Jangam et al., 2009), and the qPCR reac-
ions were run on the Stratagene Mx3005p (Agilent Technologies,
anta Clara, CA) using the FAM and Cy5 channels for data collec-
ion rather than the Abbott’s automated system, m2000spTM and
2000rt TM (Tang et al., 2007). The HIV-1 amplicon was  detected
y a 5′ﬂuorescein (FAM) conjugated probe, and the internal control
mplicon (HPR, see below) was detected by a 5′ conjugated Quasar
70 probe (Biosearch Technologies; Petaluma, CA.) Sequences
f the forward and reverse primers, hybridization probes, and
uenching oligonucleotide were described previously (Tang et al.,
007).
.5. Exogenous internal control
The internal control was adapted from the Abbott HIV-1
ealTime Assay (Abbott Molecular Inc., Des Plaines, IL). The 136-
p amplicon derived from the hydroxypyruvate reductase (HPR)
ene from the pumpkin plant (Tang et al., 2007) was  cloned into
ZErOTM-2 (Life Technologies, Carlsbad, CA). Plasmids containing
he HPR target were spiked into the PCR mastermix containing
he primers and probes for the HPR gene at 500 copies per reac-
ion. Standard curves of 8E5-LAV cells were run with and without
he primers, probe and HPR plasmid to demonstrate the con-
istency of the HIV assay. Samples that tested negative for the
IV assay and that had a failed IC were considered invalid. Sam-
les that tested positive for HIV with a failed IC were considered
ositive.
.6. Statistical analysis
Cq values were plotted against log (copy number) using Strata-
ene’s MxPro Software to obtain standard curves. Slope parameters
ere estimated by linear regression of Cq values vs log (copy
umber). For the slope estimates, 95% Conﬁdence Intervals were
btained using GraphPad Prism v 6.0 (GraphPad Software, La
olla, CA). The value of the slope was used to calculate PCR efﬁ-
iency (Lutfalla and Uze, 2006). To determine if the observed
etection of proviral DNA in this single copy study was signiﬁ-
antly different from the predicted number of samples with ≥1 a
opy according to Poisson distribution, the two-tailed P value was
alculated using Chi-square analysis using GraphPad QuickCalcs
http://graphpad.com/quickcalcs/chisquared1.cfm.)embrane disk was  sandwiched between a square 707 blotter pad and a thin sheet
araﬁlm was  centered on the Fusion 5 disk for the direct application of lysed blood
3. Results
3.1. Introduction of internal control
To monitor for the presence of ampliﬁcation inhibitors and to
verify that a negative sample is a true negative, the internal con-
trol used in the Abbott HIV-1 RealTime Assay, the hydroxypyruvate
reductase (HPR) gene from the pumpkin plant, was adapted for use
in a DNA assay. 500 copies of the HPR containing plasmid were
spiked into the qPCR mastermix. Fig. 2 demonstrates that the pres-
ence of the IC did not compete for ampliﬁcation reagents. The Cq
values obtained from the ampliﬁcation plots (Fig. 2a) were used
to plot standard curves for determination of the efﬁciencies of the
PCR. The efﬁciency with the internal control (+HPR) was calculated
to be 103% (slope −3.23; 95% conﬁdence interval −2.99 to −3.48)
(Lutfalla and Uze, 2006). The efﬁciency without the internal con-
trol (-HPR) was calculated to be 104% (slope −3.24; 95% conﬁdence
interval −3.08 to −3.40), indicating very similar assay performance
(Fig. 2b).
3.2. Determination of limits of detection and quantitation
Improvements to the assay including lysing the cells prior to
adding the sample to the ﬁlter and attaching the ﬁlter to the side
of the PCR tube were introduced. The LOD was  reported previously
to be 20 copies/100 l whole blood (200 copies/ml) (Jangam et al.,
2009). In the current test format, the 5 copy standard was detected 9
out of 9 times (Table 1) indicating that the LOD is less than 5 copies
per reaction or 50 copies/1 ml  whole blood. The internal control
Cq average 23.7 ± 0.3 (N = 52) showed no inhibition in any of the
samples.
It has been reported that 3 copies per qPCR reaction is the-
oretically the most sensitive LOD possible assuming a Poisson
distribution so that there is a 95% chance of including at least
1 copy in the PCR, and that the assay can detect a single copy






0 10 0 NA NA NA
5  9 100 0.70 0.45 −35.90
10  10 100 1.00 0.93 −6.67
20  9 100 1.30 1.26 −3.48
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Fig. 2. (a) Ampliﬁcation plots obtained from 100 l of 5 replicates HIV-1 negative whole blood spiked with 4000, 400, 40 and 10 8e5/LAV cells with and without500
c is ﬂuo











sopies/reaction of the internal control; dotted lines = +IC; solid lines = −IC. Y-axis 
alculated from ampliﬁcation plot versus log copy number of 8e5/LAV cells per 100
ymbols represent samples without IC, y = −3.24 + 30.06.
as clear that some of the samples had ampliﬁcation that was not
etected by the software because of early cycle baseline variation
aused by the presence of the ﬁlter in the PCR tube (Fig. 3a.) These
emaining samples were analyzed by examining ﬂuorescent data
ith a line ﬁt program from cycles 15–29. If the signal deviated
ig. 3. (a) Raw data ampliﬁcation plots of no template control (solid line; NTC) and
 weak positive (dotted line; well C3). (b) NTC straight line ﬁt analysis. raw
ata,  straight line ﬁt from cycles 15–29 R2 = 1, deviation from straight
ine ﬁt; (c) weak positive well C3 straight line ﬁt analysis. raw data,
traight line ﬁt from cycles 15–29 R2 = 1, deviation from straight line ﬁt.recence units and X-axis is qPCR cycle number. (b) Standard curves of Cq values
hole blood; diamond symbol represents samples with IC, y = −3.23 + 30.27; square
positively from the straight line, then the sample was called pos-
itive (Fig. 3c.) Combining this analysis with the conventionally
called Cqs, 48 (57%) of the specimens were detected as positive.
This value is close to that predicted by the Poisson distribution
of 53 (63.2%) to have ≥1copy. Assuming the proportion detected
to be normally distributed, the two  tailed P value was calculated
to be 0.26 which indicates no signiﬁcant difference between the
observed and expected number of positives in the 84 single copy
samples. Therefore, it was  concluded that the FINA assay detects a
single proviral DNA copy if present in the specimen and that the
LOD is 3 copies per qPCR reaction when processing 100 l of whole
blood.
The copy standards were also quantiﬁed using a standard curve
run on the same qPCR plate in order to estimate the LOQ. The LOQ is
deﬁned as the lowest concentration at which the analyte is not only
reliably detected but that the relative difference in quantitation
(input log copy number vs. measured log copy number) is less than
10%. A two tailed Student t-test was performed on the means of
the Cq values of 5 and 10 copies (P value = 0.0071) and of 10 and 20
copies (Pvalue = <0.0001) to determine the resolution of the assay
at these low concentrations. Ten copies can be clearly distinguished
from 5 copies; therefore, the estimated LOQ is 10 copies per reaction
or 100 copies/1 ml  whole blood.
3.3. Evaluation of FINA performance with clinical infant
specimens
To determine the sensitivity and speciﬁcity of the FINA extrac-
tion method with whole blood collected from HIV exposed infants,
the test was compared with the COBAS® Ampliprep/COBAS®
Taqman System used at the National Health Laboratory Service
Virology Laboratory, Groote Schuur Hospital, Cape Town, South
Africa. Specimens had been collected via heel stick over a 3 week
period, and 61 had more than 100 l whole blood remaining after
testing with the COBAS. The blood was processed with the FINA
modules and the ﬁlter disk containing the DNA was dried and
shipped back to U.S. for qPCR testing. One specimen did not give a
valid ampliﬁcation (the IC failed) and was  excluded from the anal-
ysis. 29 true positives and 31 true negatives were detected yielding
100% sensitivity (95% CI: 88–100%) and 100% speciﬁcity (95% CI:
89–100%). The number of copies per reaction which corresponds
to 100 l whole blood was quantiﬁed using a standard curve per-
formed on the same PCR plate (Table 2.) Two of the specimens gave
Cqs that were detectable but below the LOQ of 10 copies/100 l
(100 copies/ml) whole blood. The remainder of the positive sample
had quantiﬁable amounts of target. More than 40% of the speci-
mens had less than 50 copies per reaction or 500 copies/1 ml  whole
blood.
S.M. McFall et al. / Journal of Virologi
Table  2
Summary of quantitation of proviral DNA copy numbers from 29 HIV-1 positive
infant specimens. The copy number was calculated from a standard curve of Cq
values versus log copy number of 4000, 400, 40 and 10 8e5/LAV cells per 100 l
whole blood in triplicate. The equation of the line was y = −3.3 + 28.0; R2 = 0.996
(95% conﬁdence interval for slope is −3.4 − −3.1.).






















































peri, M.C., Pedruzzi, B., Noorjehan, A.M., Scarcella, P., Liotta, G., Palombi, L.,>1000 1 100
. Discussion
A comprehensive, simple to use, and highly sensitive assay for
he detection and quantitation of HIV-1 proviral DNA in whole
lood specimens by combining FINA extraction with the Abbott
IV-1 RealTime Assay primers and probes has been reported. The
INA method was developed for inclusion in a POC qPCR device
hich is under development for use in limited resource settings.
he Abbott primers and probes were developed to equivalently
uantify the HIV-1 group M subtypes A to H, group O and group
 isolates through a combination of the selection of a highly con-
erved target region and a mismatch tolerant probe design (Tang
t al., 2007). In this study, the introduction of an internal control
nd modiﬁcations to the FINA process are reported which greatly
mprove the analytical sensitivity of the assay to detect as few as
 copies/qPCR reaction. In a small laboratory study performed on
outh African specimens, the FINA assay demonstrated excellent
ensitivity and speciﬁcity with 100 l whole blood specimens. One
f the goals of the study was to determine if the sample input vol-
me  could be reduced from 100 l whole blood in order to reduce
he size of the DNA capture membrane. The quantitation of the
outh African specimens demonstrated that two  of the positive
amples (7%) had less than 10 copies per reaction; therefore to
aintain the high level of sensitivity from this study, we need to
aintain the input at 100 l.
A prototype of the POC qPCR system utilizing the FINA extrac-
ion was reported recently (Jangam et al., 2013.) The prototype used
 larger DNA capture membrane diameter (11 mm)  which required
 much larger qPCR reaction volume (468 l) leading to reduced
PCR sensitivity and increased reagent cost. The laboratory study
erformed on South African samples demonstrated that a diameter
f 8.35 mm which corresponds to a 100 l qPCR volume is sufﬁcient
o detect 100% of the infants, and thus a 100 l qPCR chamber can
e used. In this study because the DNA capture membrane caused
ome optical interference in the Stratagene Mx3005p, the detec-
ion of very low copy numbers required visual inspection of each
urve and a subsequent secondary analysis using a line ﬁt program.
n the POC qPCR system, the sample membrane is contained within
 polypropylene injection molded holder called the sample intro-
uction module which prevents the membrane from blocking the
ptical window (Jangam et al., 2013) thus eliminating the need for
isual inspection of each curve.
Other assays such as the COBAS® Ampliprep/COBAS® Taq-
an  System amplify both HIV-1 viral RNA and proviral DNA for
nhanced sensitivity. Efforts to improve the sensitivity of the FINA
ssay by amplifying viral RNA in addition to proviral DNA were
ot successful. The FINA method is speciﬁc for isolating genomic
NA from whole blood; it does not capture viral RNA. This was
etermined by contriving HIV-1 positive samples by spiking whole
lood with 750,000 copies/ml of HIV virus with and without
e5/LAV cells to represent cells harboring proviral DNA, andcal Methods 214 (2015) 37–42 41
RT-qPCR was  performed. Only the samples that contained proviral
cells showed ampliﬁcation which was  equivalent to the 8e5/LAV
cell control without added virus (data not shown.) The Fusion 5
membrane used in the FINA module may  capture the genomic DNA
by entangling the DNA on the ﬁlter as demonstrated by an electron
microscopy image of the Whatman FTATM card with entangled DNA
(http://www.whatman.com/FTANucleicAcidCollectionStorageand
Puriﬁcation.aspx.) It is likely that the viral RNA molecules are
either not trapped in the ﬁlter or are washed away during the
10 mM NaOH wash that removes qPCR inhibitors. Therefore, the
sensitivity of the assay cannot be improved by including a reverse
transcription step.
Detection and quantitation of proviral DNA  is becoming an
increasingly important biomarker for HIV-1 disease monitoring.
Patients receiving highly active antiretroviral treatment typically
achieve viral suppression rapidly. In recent reports from Guinea,
Malawi and Mozambique showed that 85% of the people receiving
antiretroviral treatment had viral suppression within six months
(De Luca et al., 2012). Alternative methods are needed to allow
further evaluation of therapy efﬁcacy as well as compare different
treatment regimens in clinical trials (Christopherson et al., 2000).
In a preliminary study, the FINA extraction with the Abbott Real-
Time PCR primers and probes was demonstrated to sensitively and
speciﬁcally detect proviral DNA in adults as well as infants. Proviral
DNA was detected in 72/75 HIV-1 positives specimens tested (96%
sensitivity; 95% CI: 89–99%). This study was  performed with the
earlier version of FINA which had an LOD of 200 copies/ml rather
than 30 copies/ml whole blood and did not allow accurate quantita-
tion of the specimens. A high throughput version of this improved
assay could prove to be useful in monitoring treatments aimed at
HIV eradication. Additionally, the FINA extraction could be adapted
for use with other inputs besides peripheral blood to look for reser-
voirs of HIV-1 infected cells. HIV proviral testing could also be used
to screen vaccine trial subjects for true infection.
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